Innovator’s Pitch Challenge
We are developing an ‘end-to-end’ diagnostic microfluidic platform to address the omnipresent burden of drug resistant bacterial and fungal infections, 2.8M in the US last year alone, by providing the information clinicians need to treat patients in hours, not days. Our next generation microfluidic point of care diagnostic platform will rapidly identify, ~30 minutes, a pathogen from a clinical specimen, and then determines the pathogen’s antimicrobial susceptibility within 30-45 additional minutes. Our platform is based off of two pieces of acoustic technology developed at Sandia National Laboratories.
Contact Us:
Matt Jones
matt.jones@resonantiadx.com